home / stock / sngx / sngx news

SNGX News and Press, Soligenix Inc. From 04/09/19

Stock Information
Company Name: Soligenix Inc.
Stock Symbol: SNGX
Market: NASDAQ
Website: soligenix.com
Menu
SNGX SNGX Quote SNGX Short SNGX News SNGX Articles SNGX Message Board
Get SNGX Alerts

News, Short Squeeze, Breakout and More Instantly...
SNGX - EMA reaches agreement with Soligenix for SGX942 PIP; shares up 10% premarket

The Pediatric Committee (PDCO) of the EMA has agreed to Soligenix's (NASDAQ: SNGX ) Pediatric Investigation Plan (PIP) for SGX942 (dusquetide). The Company may defer conducting the PIP until successful completion of Phase 3 clinical study evaluating SGX942 as a treatment for oral mucositis...
SNGX - Soligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942

PRINCETON, N.J. , April 9, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today...

SNGX - Soligenix nabs new patent in U.S.; shares up 10% premarket

The USPTO will issue Soligenix (NASDAQ: SNGX ) new patent titled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity" on April 9. More news on: Soligenix, Inc., Healthcare stocks news, Stocks on t...

SNGX - Soligenix Receives US Patent for Dusquetide Related Analogs

PRINCETON, N.J. , April 4, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the US Pat...
SNGX - Soligenix Announces Recent Accomplishments and Year-End 2018 Financial Results

PRINCETON, N.J. , March 26, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its ...

SNGX - Soligenix to Present at National Institutes of Health - Commercialization Accelerator Program "FeedForward Session" in Washington, DC

PRINCETON, N.J. , March 18, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that...

SNGX - Soligenix to Present at the Boston Oncology Investor Conference 2019

PRINCETON, N.J. , March 11, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its ...
SNGX - Soligenix nabs patent in U.S. protecting Rivax; shares up 14% premarket

Soligenix (NASDAQ: SNGX ) has received a notice of allowance for a new U.S. patent protecting its ricin toxin vaccine, RiVax. More news on: Soligenix, Inc., Healthcare stocks news, Stocks on the move, Read more ...

SNGX - Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®

PRINCETON, N.J. , Feb. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the a...

SNGX - Soligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate

PRINCETON, N.J. , Feb. 7, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today public...
Previous 10 Next 10